Gepotidacin is the first in a new class of oral antibiotics for uUTIs in nearly 30 years. The approval was supported by results of the phase 3 EAGLE-2 and EAGLE-3 trials. The FDA approved ...

The regulatory decision announced Tuesday covers the treatment of female adults and pediatric patients age 12 and older who have uncomplicated urinary tract infections, or uUTIs. The drug ...

GSK's Blujepa (gepotidacin) becomes the first in a new class of oral antibiotics to treat uncomplicated UTIs (also known as uUTIs) in almost 30 years, taking aim at infection-causing bacteria ...

GSK plc GSK announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract infections (uUTIs) in female adults and adolescents. A commercial launch ...

The FDA has approved GSK’s Blujepa (gepotidacin), a first-in-class oral antibiotic for the treatment of uncomplicated urinary tract infections (uUTIs) in female adults and patients over 12 years of ...

“The approval of Blujepa is a crucial milestone with uUTIs among the most common infections in women,” Tony Wood, GSK’s chief scientific officer, said in a statement. “We are proud to have ...

Gepotidacin is the first new class of oral antibiotics for uUTIs in nearly 30 years, addressing rising drug resistance. Phase 3 trials showed gepotidacin's non-inferiority to nitrofurantoin ...

TUESDAY, March 25, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult ...